ClinicalTrials.gg
CompletedNCT00884312Updated May 14, 2018Results posted

A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols

A Phase 2 interventional study of Carfilzomib in Multiple Myeloma and Solid Tumors, sponsored by Amgen. Completed at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-14.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
27th of 113
101 · median 54
Started
2009
with 1 other
Phase 2
50 of 113
6 open now
Registered
7th of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 27th largest by enrollment, is one of 2 that started in 2009, is one of 50 in phase 2, and was the 7th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a multi-center, open-label, Phase 2 study of carfilzomib to monitor the safety and efficacy of long-term or continuing carfilzomib therapy for patients who previously completed a primary carfilzomib treatment study.

03

Conditions studied

  • Multiple Myeloma
  • Solid Tumors

Browse trials for

Keywords

  • Multiple myeloma
  • proteasome
  • Hematological
  • carfilzomib
  • PR-171
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Previous completion of a carfilzomib study within 90 days prior to first dose of maintenance study drug.
  2. Disease Assessments performed within 30 days prior to first dose of maintenance study drug.
  3. Written in accordance with federal, local, and institutional guidelines
  4. Females of (FCBP) must have a negative serum or urine pregnancy test, with a sensitivity of at least 50 mIU/mL, within 3 days prior to first dose of maintenance study drug.
  5. Subjects must agree to adhere to the study visit schedule and other study requirements and receive outpatient treatment and laboratory monitoring at the institution that administers the drug.

Exclusion criteria

Exclusion Criteria:

  1. Administration of an intervening chemotherapy between the time of previous carfilzomib study termination and first dose of maintenance study drug.
  2. Pregnant or lactating females
  3. Diagnosis of a new of a different tumor type.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Carfilzomib

    Participants received carfilzomib administered intravenously, using the same method, frequency, and dose level as in the last cycle of the participant's previous carfilzomib study. Treatment was continued until confirmation of disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or commercial availability of carfilzomib.

    Drug: Carfilzomib

Interventions

  • Carfilzomib dose levels ranged from 11 to 27 mg/m² for 2- to 10-minute infusions and 36 to 56 mg/m² for 30-minute infusions. Carfilzomib doses were administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Dose level reduction to a minimum dose of 11 mg/m² for toxicity was permitted.

    Also known as: PR-171, PR171, Kyprolis®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Peripheral Neuropathy

    Participants with peripheral neuropathy or peripheral neuropathy-related adverse events, including hypoaesthesia, paraesthesia, dysaesthesia, and neuropathic pain.

    Time frame: From first dose of study drug to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.

  2. Number of Participants With Adverse Events

    Adverse events (AEs) were assigned a severity grade using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grading scale version 3.0. Per protocol, adverse events were collected if they led to dose modification or dose discontinuation, were grade ≥ 3 or serious, or were events of peripheral neuropathy (any grade). A serious AE is one that met one or more of the following criteria: * Death * Life threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect in the offspring of an exposed subject * Important medical events that, based upon appropriate medical judgment, jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes above.

    Time frame: From first dose of study drug to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.

Secondary outcomes

  1. Overall Survival

    Since participants were only followed up to 30 days after administration of last dose of study drug per protocol, Kaplan-Meier estimates of overall survival were not calculated. The number of participants who died within 30 days after administration of last dose of study drug is reported.

    Time frame: From first dose of study drug to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.

  2. Progression-free Survival

    Progression-free survival (PFS) was defined as the time between the start of treatment and first evidence of documented disease progression or death (due to any cause), whichever occurred first. Disease progression was determined by the local investigator for regimens with the same baseline using the International Uniform Response Criteria (IMWG-URC) for participants with multiple myeloma and Response Evaluation Criteria in Solid Tumors (RECIST) criteria for solid tumor participants. PFS was re-calculated whenever the baseline was reset due to addition of new anti-cancer therapy or increase of carfilzomib dose/frequency.

    Time frame: From first dose of study drug in study PX-171-010 to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.

  3. Time to Progression

    Time to progression (TTP) was defined as the time between start of treatment to the first documentation of disease progression. TTP was re-calculated whenever the baseline was reset due to addition of new anti-cancer therapy or increase of carfilzomib dose/frequency.

    Time frame: From first dose of study drug in study PX-171-010 to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.

07

Results

Posted May 14, 2018

Participant flow

This study was conducted at 23 centers in the United States and Canada from April 2009 to May 2017.

Participant flow — Overall Study
MilestoneSolid TumorsMultiple Myeloma
Started992
Received treatment991
Completed767
Not completed225
Withdrew: Non-fatal progressive disease08
Withdrew: Fatal progressive disease01
Withdrew: Non-fatal adverse event10
Withdrew: Fatal adverse event14
Withdrew: Withdrawal by subject06
Withdrew: Physician decision01
Withdrew: Other04
Withdrew: Did not receive study drug01

Outcome measures

PrimaryNumber of Participants With Peripheral Neuropathy

Participants with peripheral neuropathy or peripheral neuropathy-related adverse events, including hypoaesthesia, paraesthesia, dysaesthesia, and neuropathic pain.

Time frame:
From first dose of study drug to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.
Reported as:
Number · participants
Number of Participants With Peripheral Neuropathy
participantsSolid TumorsMultiple Myeloma
Number of Participants With Peripheral Neuropathy115
PrimaryNumber of Participants With Adverse Events

Adverse events (AEs) were assigned a severity grade using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grading scale version 3.0. Per protocol, adverse events were collected if they led to dose modification or dose discontinuation, were grade ≥ 3 or serious, or were events of peripheral neuropathy (any grade). A serious AE is one that met one or more of the following criteria: * Death * Life threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect in the offspring of an exposed subject * Important medical events that, based upon appropriate medical judgment, jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes above.

Time frame:
From first dose of study drug to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsSolid TumorsMultiple Myeloma
Any adverse event784
Adverse event ≥ grade 3566
Serious adverse events557
Fatal adverse events17
AE leading to discontinuation of carfilzomib520
SecondaryOverall Survival

Since participants were only followed up to 30 days after administration of last dose of study drug per protocol, Kaplan-Meier estimates of overall survival were not calculated. The number of participants who died within 30 days after administration of last dose of study drug is reported.

Time frame:
From first dose of study drug to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.
Reported as:
Number · participants
Overall Survival
participantsSolid TumorsMultiple Myeloma
Overall Survival17
SecondaryProgression-free Survival

Progression-free survival (PFS) was defined as the time between the start of treatment and first evidence of documented disease progression or death (due to any cause), whichever occurred first. Disease progression was determined by the local investigator for regimens with the same baseline using the International Uniform Response Criteria (IMWG-URC) for participants with multiple myeloma and Response Evaluation Criteria in Solid Tumors (RECIST) criteria for solid tumor participants. PFS was re-calculated whenever the baseline was reset due to addition of new anti-cancer therapy or increase of carfilzomib dose/frequency.

Time frame:
From first dose of study drug in study PX-171-010 to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.
Reported as:
Median · months
Progression-free Survival
monthsSolid TumorsMultiple Myeloma
Progression-free Survival41.9 (NA to NA)19.6 (10.2 to 30.6)
SecondaryTime to Progression

Time to progression (TTP) was defined as the time between start of treatment to the first documentation of disease progression. TTP was re-calculated whenever the baseline was reset due to addition of new anti-cancer therapy or increase of carfilzomib dose/frequency.

Time frame:
From first dose of study drug in study PX-171-010 to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.
Reported as:
Median · months
Time to Progression
monthsSolid TumorsMultiple Myeloma
Time to ProgressionNA (NA to NA)19.6 (10.2 to 30.6)

Adverse events

Collected over From first dose of study drug to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Solid Tumors1/9 (11.1%)5/9 (55.6%)6/9 (66.7%)
Multiple Myeloma7/91 (7.7%)57/91 (62.6%)69/91 (75.8%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventSolid TumorsMultiple Myeloma
Cardiac tamponadeCardiac disorders1/90/91
CardiomyopathyCardiac disorders1/90/91
Herpes zoster ophthalmicInfections and infestations1/90/91
InfectionInfections and infestations1/90/91
PneumoniaInfections and infestations1/910/91
SepsisInfections and infestations1/93/91
ArthralgiaMusculoskeletal and connective tissue disorders1/91/91
Renal failure acuteRenal and urinary disorders1/94/91
Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders1/90/91
InfluenzaInfections and infestations0/96/91
Most frequent other events
Showing 10 of 46
Most frequent other events
EventSolid TumorsMultiple Myeloma
VomitingGastrointestinal disorders3/95/91
FatigueGeneral disorders3/916/91
Upper respiratory tract infectionInfections and infestations1/921/91
NauseaGastrointestinal disorders2/911/91
PyrexiaGeneral disorders2/94/91
NasopharyngitisInfections and infestations2/91/91
DyspnoeaRespiratory, thoracic and mediastinal disorders2/914/91
NeutropeniaBlood and lymphatic system disorders0/919/91
AnaemiaBlood and lymphatic system disorders0/918/91
ThrombocytopeniaBlood and lymphatic system disorders0/916/91

Baseline characteristics

All participants who received at least 1 dose of carfilzomib after enrollment in PX-171-010.

Age, Continuous
Age, Continuous(years)Solid TumorsMultiple MyelomaTotal
Mean61.2 ± 12.7563.2 ± 9.8263.0 ± 10.05
Age, Customized
Age, Customized(Participants)Solid TumorsMultiple MyelomaTotal
< 65 years54752
≥ 65 years44448
Sex: Female, Male
Sex: Female, Male(Participants)Solid TumorsMultiple MyelomaTotal
Female63844
Male35356
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Solid TumorsMultiple MyelomaTotal
White97180
Black01111
Hispanic055
Asian/Pacific Islander044
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Solid TumorsMultiple MyelomaTotal
0 (Fully active)63945
1 (Restricted but ambulatory)34245
2 (Ambulatory but unable to work)01010
08

Study locations

23 sites
  • Pinnacle Oncology Hematology
    Scottsdale, Arizona 85258, United States
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211, United States
  • City of Hope National Medial Center
    Duarte, California 91010, United States
  • University of California Medical Center
    San Francisco, California 94143, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612, United States
  • Winship Cancer Institute - Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Maryland, Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110-1093, United States
  • John Theurer Cancer Center at Hackensack UMC
    Hackensack, New Jersey 07601, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Abramson Cancer Center of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203-1632, United States
  • Texas Oncology Cancer Center
    Austin, Texas 78731, United States
  • The University of Texas, MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Northwest Cancer Center
    Houston, Texas 77090, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • University of Toronto, Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Jewish General Hospital
    Montreal, Quebec H3t 1E2, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2009 to primary completion in May 2017, 97 months.

Results were first posted in May 2018, 11 months after primary completion.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 97 months is above that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2009
First posted
Apr 20, 2009
StartActual
Apr 9, 2009
Primary completionActual
May 17, 2017
CompletionActual
May 17, 2017
Results first posted
May 14, 2018
Last update
May 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00884312
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 20, 2009
Start date
Apr 9, 2009
Primary completion
May 17, 2017
Completion
May 17, 2017
Results posted
May 14, 2018
Last update
May 14, 2018

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion